Akpinar Abdullah, Özdamar Ünal Gülin, Atay İnci Meltem, Gündoğar Duru, Özçankaya Ramazan
Süleyman Demirel University Faculty of Medicine, Department of Psychiatry, Isparta, Turkey.
Noro Psikiyatr Ars. 2013 Dec;50(4):372-374. doi: 10.4274/npa.y6439. Epub 2013 Dec 1.
Late-life onset manic attacks generally occur secondary to general medical conditions or drug use. Varenicline is an α4β2 nicotinic acetylcholine receptor partial agonist, used for the cessation of smoking. In this case report, we present a 67-year-old male patient with a new-onset manic episode following varenicline treatment. The patient's manic symptoms started on the seventh day of varenicline treatment. His symptoms started on the 7th day of treatment. He was admitted to the psychiatric outpatient clinic since his symptoms did not improve despite discontinuing varenicline treatment. In the initial mental status examination, he scored 35/60 on the Young Mania Rating Scale (YMRS). On the twenty-fifth day of the hospitalization, the patient was discharged since his YMRS score improved (5/60). Varenicline may cause manic episodes in patients with bipolar disorder and in healthy individuals. An increasing number of serious psychiatric disorders are being reported due to varenicline treatment. Mental state examination before and during varenicline treatment seems necessary.
老年期躁狂发作通常继发于一般躯体疾病或药物使用。伐尼克兰是一种α4β2烟碱型乙酰胆碱受体部分激动剂,用于戒烟。在本病例报告中,我们介绍了一名67岁男性患者,在使用伐尼克兰治疗后出现新发躁狂发作。患者的躁狂症状在伐尼克兰治疗的第7天开始出现。他的症状在治疗第7天开始。尽管停用了伐尼克兰治疗,但症状仍未改善,因此他被收治到精神科门诊。在初始精神状态检查中,他在杨氏躁狂评定量表(YMRS)上得分为35/60。住院第25天,由于他的YMRS评分改善(5/60),患者出院。伐尼克兰可能会在双相情感障碍患者和健康个体中引起躁狂发作。由于伐尼克兰治疗,报告的严重精神障碍数量越来越多。在伐尼克兰治疗前和治疗期间进行精神状态检查似乎很有必要。